AI-Summary – News For Tomorrow
Gilead Sciences is constructing a new pharmaceutical development and manufacturing hub at its Foster City headquarters, part of a $32 billion investment in US manufacturing. This move aligns with similar initiatives by other major drugmakers like Eli Lilly and Johnson & Johnson, spurred by potential tariffs and President Trump’s push for domestic production. Gilead’s 180,000-square-foot facility is part of a broader expansion, including a research building and a biologics manufacturing site. The company estimates that these investments will generate over 3,000 jobs and contribute $43 billion to the US economy by 2030.
News summary provided by Gemini AI.
(Reuters) -Gilead Sciences said on Wednesday it has started work on a new pharmaceutical development and manufacturing hub at its headquarters in Foster City, California, as part of its planned $32 billion investment in domestic manufacturing.
Major U.S. drugmakers such as Eli Lilly, Johnson & Johnson, Merck and Bristol Myers Squibb have also announced big investments this year to boost domestic production, as tariffs threaten to raise costs and President Donald Trump pushes to bring more manufacturing to America.
Gilead’s five-story, 180,000-square-foot facility “is part of our vision for delivering next generation therapies,” said CEO Daniel O’Day.
In addition to Gilead’s Bay Area facility, the company is currently developing two other sites – a research building to accelerate scientific discovery, already under construction, and a biologics manufacturing facility to expand domestic production capacity.
Gilead said on Wednesday its investments through 2030 will create more than 3,000 direct and indirect jobs, and $43 billion in value to the U.S. economy.
(Reporting by Puyaan Singh in Bengaluru; Editing by Devika Syamnath)
